Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Enforceable Diagnostic Method Patents: Though ITC Provides Some Protection Abroad, States Can Trample Rights Here at Home

main

Enforceable Diagnostic Method Patents

Enforceable Diagnostic Method Patents: Though ITC Provides Some Protection Abroad, States Can Trample Rights Here at Home | Insights & Resources | Goodwin

Enforceable Diagnostic Method Patents: Though ITC Provides Some Protection Abroad, States Can Trample Rights Here at Home

Related Content

Alexion and Samsung Settle Eculizumab BPCIA Case

Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and Post-Patent Expiration Royalty Obligations

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

The Centers for Medicare & Medicaid Services Announces Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation

PTAB Institutes Sarepta’s IPR

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

Update on Recent International Biosimilar Approvals

Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar

SOLASTA Bio Completes $14m Series A

Goodwin Advises Bicara’s $362 Million Upsized Initial Public Offering

Goodwin Advises MBX Biosciences in Upsized Initial Public Offering

Cognitive Credit Completes $10 Million Series B Funding

Montage Ventures Leads CardiaTec’s $6.5 Million Seed Round

Clients Name Goodwin an Intimidating Opponent in BTI Consulting’s Most Feared Law Firms in Litigation List

Goodwin Represents Underwriters On PACS Group’s Completed Upsized $690 Million Public Offering

Goodwin Scales Life Sciences and Technology Platform in Paris with Capital Markets Partner Guilhem Richard

Life Sciences

Technology